Is Anti-Hepatitis C Virus Antibody Level an Appropriate Marker to Preclude the Need for Supplemental Testing?

Publisher： Karger

E-ISSN： 1423-0100|58|5|310-317

ISSN： 0300-5526

Source： Intervirology, Vol.58, Iss.5, 2015-0, pp. : 310-317

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Value anti–hepatitis C virus therapy by its clinical efficacy

By  

HEPATOLOGY, Vol. 62, Iss. 2, 2015-08 ,pp. : 334-336

John Wiley & Sons Inc

Access to resources Recommend Favorite

Low Prevalence of Anti-Hepatitis C Virus Antibodies in Mexico: A Systematic Review

By  

Intervirology, Vol. 50, Iss. 1, 2006-11 ,pp. : 1-8

Karger

Access to resources Recommend Favorite

Optimal duration of pre‐liver transplantation anti‐hepatitis C virus treatment with direct‐acting agent sofosbuvir

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 6, 2015-06 ,pp. : 1776-1776

John Wiley & Sons Inc

Access to resources Recommend Favorite

The case for cost‐effectively treating cryoglobulinemic vasculitis with interferon‐free anti–hepatitis C virus therapy

By  

HEPATOLOGY, Vol. 62, Iss. 3, 2015-09 ,pp. : 975-975

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prevention of hepatitis C virus infection and spread in human liver chimeric mice by an anti‐CD81 monoclonal antibody

By  

HEPATOLOGY, Vol. 61, Iss. 4, 2015-04 ,pp. : 1136-1144

John Wiley & Sons Inc

Access to resources Recommend Favorite